SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing significant discussion and extreme volatility after Novo Nordisk filed a patent infringement lawsuit over its compounded semaglutide products, which Hims has since ceased, with the community sharply divided between concerns over legal and regulatory risks and the belief that the stock is oversold with short-squeeze potential.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending due to a striking disconnect between recent strong earnings, profitability, and a $500M share buyback, and an unprecedented streak of red daily candles pushing the stock to historic lows. Community sentiment is fiercely divided on whether this presents a generational buying opportunity fueled by its AI/AR smartglasses vision and a potential short squeeze, or if persistent management issues will continue to suppress its value.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending after issuing weaker-than-expected revenue guidance for the current quarter and fiscal year, despite a strong earnings beat, intensifying investor concerns that AI is disrupting the traditional software business model. The community is sharply divided, with many viewing the steep selloff as an overreaction and a buying opportunity given the company's cash position, while others remain cautious about AI's long-term impact on the SaaS sector.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl is trending after a sharp stock drop driven by a deteriorated financial outlook, unexpected leadership changes, a delayed filing, and an SEC probe into its accounting practices, leading to a community split between those seeing an oversold buying opportunity and others fearing significant financial irregularities.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending following its all-stock acquisition of Valaris, a $5.8 billion deal set to create a combined $17 billion offshore drilling industry leader. The community is actively discussing the potential for a strengthened fleet and significant cost savings to capitalize on an emerging upcycle, though some express concerns over shareholder dilution.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending down sharply after its mixed Q4 earnings report, featuring a revenue miss and conservative forward guidance. This has ignited intense community debate over whether the fintech stock is now severely undervalued and a buying opportunity, or if the market is overreacting amidst broader sector weakness.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio (RGNX) is trending due to a clinical hold placed on its RGX-121 and RGX-111 gene therapy programs following a potential tumor link with the AAV vector, just days before RGX-121's critical PDUFA date. The community is intensely debating whether an imminent Complete Response Letter or a delay is inevitable, with many expecting significant downside, while others highlight the company's other pipeline assets as the true value drivers.

Tokenized asset from Ondo Finance representing BigBear.ai Holdings (Ondo Tokenized).

BigBear.ai Holdings (Ondo Tokenized Stocks)

BigBear.ai Holdings (Ondo Tokenized Stocks) is trending as the community actively discovers and discusses this tokenized asset, prompting questions about its existence, the broader implications of such financial instruments, and its potential relationship to the underlying NYSE-listed BBAI stock.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following an 'Overweight' initiation and bullish price target from Morgan Stanley, amplifying the narrative around its strategic pivot to AI and high-performance computing data centers. The community is actively discussing the company's strong power infrastructure and key partnerships, like Google, positioning it favorably amidst booming demand for computing capacity, despite some noting its historical correlation with Bitcoin prices.

Valaris Ltd. engages in the provision of offshore contract drilling services to the international oil and gas industry. It operates through the following segments: Floaters, Jackups, ARO, and Other. The Floaters segment includes drillships and semisubmersible rigs. The Other segment is involved in management services on rigs owned by third-parties and the activities associated with arrangements with ARO under the bareboat charter arrangements. The company was founded in 1975 and is headquartered in Hamilton, Bermuda.

Valaris Ltd

Valaris is trending following the announcement of its all-stock acquisition by Transocean for approximately $5.8 billion, leading to significant community discussion around the deal's implications for shareholders and warrants. This M&A activity coincides with Valaris securing substantial new drilling contracts and ongoing conversations about a strengthening offshore energy sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Each Series AA share can convert into 20 common shares, while Series AAA shares can convert into 150.</li><li>Alongside the investment, David E. Lazar has been named Co-Chief Executive Officer and Chairman of the Board.</li><li>The company plans to use the funds raised from the offering to support daily operations, cover severance, and manage general corporate needs.&nbsp;</li></ul>Indaptus Therapeutics Inc. (INDP) announced on Monday that it has secured a $6 million investment through the sale of non-voting convertible preferred stock to investor David E. Lazar.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/INDP">Indaptus’ stock</a> traded over 12% higher. However, on Stocktwits, retail sentiment around the stock changed to ‘bearish’ from ‘extremely bearish’ territory the previous day amid ‘extremely low’ message volume levels.&nbsp;<h2 class="st-heading-2">Transaction Details&nbsp;</h2>The investment, finalized on December 23, includes 300,000 Series AA preferred shares and 700,000 Series AAA preferred shares. Each Series AA share can convert into 20 common shares, while Series AAA shares can convert into 150, pending stockholder approval expected in the first-quarter (Q1) 2026.<blockquote>"In making this significant investment in Indaptus, I look forward to continuing to evaluate the company’s lead product candidate while actively exploring strategic opportunities to drive value for our stockholders.”-David E. Lazar, Investor</blockquote>Alongside the investment, David E. Lazar has been named Co-Chief Executive Officer and Chairman of the Board. Once stockholder approval is received, Lazar can nominate up to three additional directors.<h2 class="st-heading-2">Strategic Implications</h2>The company plans to use the funds raised from the offering to support daily operations, cover severance, manage general corporate and working capital needs, and pay offering-related costs, including securing stockholder approval.Indaptus develops Decoy, a patented, antigen-agnostic immunotherapy using attenuated Gram-negative bacteria to activate innate and adaptive immune responses. Preclinical studies show tumor and viral eradication, enhanced by combinations with checkpoint inhibitors or chemotherapy.Indaptus’ Decoy platform activates and matures multiple human immune cells in vitro, exhibits low toxicity upon intravenous administration, and demonstrates promising single-agent activity against chronic hepatitis B and HIV in preclinical studies.INDP stock has declined by over 90% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/soft-bank-acquires-digital-bridge-for-4-billion-to-scale-ai-infrastructure/cL75v6iREx9">SoftBank Acquires DigitalBridge For $4 Billion To Scale AI Infrastructure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did INDP Stock Gain 12% Today?

The company has secured a $6 million investment from investor David E. Lazar via the sale of non-voting convertible preferred stock. 

Equity

The company has secured a $6 million investment from investor David E. Lazar via the sale of non-voting convertible preferred stock. 


What Does the Market Think About Indaptus Therapeutics Inc?

Biotech Stocks To Keep An Eye On - December 24th

Abivax, Indaptus Therapeutics, Danaher, Vertex Pharmaceuticals, Moderna, argenex, and Amicus Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today

INDP, PATH, TRIB, SOC, MCD were among the stocks seen among investors on Tuesday, Dec. 23, 2025.read more...

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Indaptus Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

INDP
Indaptus Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest INDP News

INDPIndaptus Therapeutics Inc